ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
2.
Perkovic et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.
-
3.
Zelniker TA , et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393, 10166: P31–39.
-
5.
de Zeeuw , et al.. Renal trials in diabetes need a platform: time for a global approach? Lancet Diabetes and Endocrinology 2018; 6:P356–358.
New Directions in Diabetic Kidney Disease Trials
Vlado Perkovic
Vlado Perkovic
Vlado Perkovic, MBBS, PhD, is Executive Director of The George Institute, Australia, Professor of Medicine at UNSW Sydney, and a staff specialist in nephrology at the Royal North Shore Hospital.
Search for other papers by Vlado Perkovic in
Current site
Google Scholar
PubMed
Search for other papers by Vlado Perkovic in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory
Powered by PubFactory